A study to find out how safe is it to give people with asthma a new medicine called MTPS9579A

  • Asthma
Trial Status:

Completed

This trial runs in
Cities
  • Birmingham
  • Glasgow
  • Leicester
  • London
  • Manchester
Trial Identifier:

GA41003

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This clinical trial was done to study a new medicine (MTPS9579A) for the treatment of asthma, to find out if it was safe for people with asthma. Other information researchers wanted to know included the concentration of MTPS9579A in the body after dosing, whether MTPS9579A was effective, and if the body made antibodies when exposed to MTPS9579A. Twenty-seven people who had asthma took part in this study at six study centers in one country.

      Genentech, Inc., USA. (Part of F. Hoffmann-La Roche Ltd., Switzerland). Sponsor
      Phase 1c Phase
      GA41003 Trial Identifier
      All Gender
      18 to 65 Years Age
      No Healthy Volunteers

      People with asthma requiring inhaled corticosteroids and a second controller were enrolled at six study sites in one country to evaluate the safety and tolerability of MTPS9579A, an antibody drug against tryptase. Twenty-seven participants completed the study and comprised the safety-evaluable population. This was a Phase 1c, multicenter, randomized, observer-blinded, placebo-controlled study. Results showed MTPS9579A to be tolerable with no drug-related serious side effects or drug-related non-serious side effects. The Sponsor is no longer developing MTPS9579A for asthma. This decision had nothing to do with the safety of the medicine.

      Trial Summary

      This clinical trial was done to study a new medicine (MTPS9579A) for the treatment of asthma, to find out if it was safe for people with asthma. Other information researchers wanted to know included the concentration of MTPS9579A in the body after dosing, whether MTPS9579A was effective, and if the body made antibodies when exposed to MTPS9579A. Twenty-seven people who had asthma took part in this study at six study centers in one country.

      Genentech, Inc., USA. (Part of F. Hoffmann-La Roche Ltd., Switzerland). Sponsor
      Phase 1c Phase
      GA41003 Trial Identifier
      MTPS9579A Treatments
      Asthma Condition
      Official Title

      A phase 1c, multicenter, randomized, observer-blinded, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of a single dose of MTPS9579A in patients with asthma requiring inhaled corticosteroids and a second controller

      Eligibility Criteria

      All Gender
      18 to 65 Years Age
      No Healthy Volunteers

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Trials

      Use our search to find other trials on Genentech Clinical Trials in related disease areas.

      Asthma

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now